Sanofi-Aventis shelves 14 R&D programmes; sales up
This article was originally published in Scrip
Executive Summary
Sanofi-Aventis has discontinued, halted or returned the rights to 14 R&D projects currently in its pipeline as its CEO Chris Viehbacher continues to overhaul the business.